Creso Pharma Limited announced it has secured a commercialization agreement with Precision Healthcare Ltd. to market and distribute Creso Pharma's cannaQIX®10 and 50 hemp-based human health nutraceutical products in the UK. The UK launch of cannaQIX®10 and 50 is planned for first quarter of 2018. The agreement covers the non-exclusive marketing and distribution of cannaQIX®10 and 50 in the UK market, targeting pharmacies and health food stores.